Highlights from our recent research

As UK and European (re)insurers reassess their foreign-currency risk exposures, we present high-level insights from a survey of industry executives.
A proposed change to OPPS payments for 340B drugs could have material financial effects on non-340B hospitals, Medicare Advantage plans, and beneficiaries.

In our eighth edition of a report on capital regimes in Asia, we cover existing conditions and upcoming changes across the region.